Search results
U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio...
FOX 23 News Albany· 3 days agoApproval supported by two Phase 3 clinical trials that evaluated SKYRIZI® for the treatment of moderate to severe ulcerative colitis: a 12-week induction study, INSPIRE,1 and a 52-week maintenance ...
Previously Unknown Immune System Link Uncovered – Findings Could Lead to New Cancer Treatments
SciTechDaily· 4 days agoWeill Cornell scientists discovered a crucial link between two immune pathways involving IL-23 and...
Putting the brakes on chronic inflammation | Cornell Chronicle
Cornell News Service· 4 days agoThe immune system has many pathways to protect the body from infection, but sometimes an overactive...